These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16340380)

  • 1. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients.
    Strous RD; Maayan R; Kotler M; Weizman A
    Clin Neuropharmacol; 2005; 28(6):265-9. PubMed ID: 16340380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
    Strous RD; Maayan R; Lapidus R; Stryjer R; Lustig M; Kotler M; Weizman A
    Arch Gen Psychiatry; 2003 Feb; 60(2):133-41. PubMed ID: 12578430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
    Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Nachshoni T; Ebert T; Abramovitch Y; Assael-Amir M; Kotler M; Maayan R; Weizman A; Strous RD
    Schizophr Res; 2005 Nov; 79(2-3):251-6. PubMed ID: 16126372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
    Ritsner M; Gibel A; Ram E; Maayan R; Weizman A
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):137-46. PubMed ID: 16139994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
    Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2007; 58(3):213-9. PubMed ID: 17940987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study.
    Caufriez A; Leproult R; L'Hermite-Balériaux M; Kerkhofs M; Copinschi G
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):716-24. PubMed ID: 23488643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
    Morales AJ; Haubrich RH; Hwang JY; Asakura H; Yen SS
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):421-32. PubMed ID: 9876338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
    Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
    Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology.
    Strous RD; Maayan R; Lapidus R; Goredetsky L; Zeldich E; Kotler M; Weizman A
    Schizophr Res; 2004 Dec; 71(2-3):427-34. PubMed ID: 15474914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
    Ritsner MS; Strous RD
    J Psychiatr Res; 2010 Jan; 44(2):75-80. PubMed ID: 19665142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients.
    Ritsner M; Maayan R; Gibel A; Strous RD; Modai I; Weizman A
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):267-73. PubMed ID: 15163435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia.
    Ritsner M; Gibel A; Maayan R; Ratner Y; Ram E; Biadsy H; Modai I; Weizman A
    Neuropsychopharmacology; 2005 Oct; 30(10):1913-22. PubMed ID: 15870835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.
    Libè R; Barbetta L; Dall'Asta C; Salvaggio F; Gala C; Beck-Peccoz P; Ambrosi B
    J Endocrinol Invest; 2004 Sep; 27(8):736-41. PubMed ID: 15636426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women.
    Basu R; Dalla Man C; Campioni M; Basu A; Nair KS; Jensen MD; Khosla S; Klee G; Toffolo G; Cobelli C; Rizza RA
    Diabetes; 2007 Mar; 56(3):753-66. PubMed ID: 17327446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology.
    Strous RD
    Essent Psychopharmacol; 2005; 6(3):141-7. PubMed ID: 15869021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences.
    Bloch M; Meiboom H; Zaig I; Schreiber S; Abramov L
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):910-8. PubMed ID: 23084789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary heart disease--preliminary study].
    Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):904-10. PubMed ID: 16821209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short-term DHEA intake on hormonal responses in young recreationally trained athletes: modulation by gender.
    Collomp K; Buisson C; Gravisse N; Belgherbi S; Labsy Z; Do MC; Gagey O; Dufay S; Vibarel-Rebot N; Audran M
    Endocrine; 2018 Mar; 59(3):538-546. PubMed ID: 29322301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.